Trends in Hospital Charging Practices from 2019-2022 Among Hospitals with and without Chimeric Antigen Receptor (CAR) T-Cell Therapy Utilization

Speaker(s)

Snyder S, McBride K, Gitlin M
BluePath Solutions, Los Angeles, CA, USA

OBJECTIVES: Original Medicare (Fee-for-service, FFS) reimbursement in the inpatient setting of care can be impacted by the hospital cost-to-charge ratio (CCR) used for a given claim. This study evaluated differences and trends in CCRs among hospitals that utilized chimeric antigen receptor (CAR) T-cell therapies compared to hospitals with little to no CAR T utilization between 2019-2022.

METHODS: Medicare FFS research identifiable files (RIF, claims) data were used to identify hospitals with at least 11 CAR T claims in each calendar year (“CAR T providers”). Healthcare Cost Report Information System (HCRIS) data were used to obtain CCRs for all hospitals. Descriptive statistics on the Medicare inpatient CCR were presented for CAR T providers and other hospitals. Repeated measures ANOVA with Bonferroni adjustment tested whether the mean Medicare inpatient CCR was the same between CAR T providers and other hospitals each year. A simple linear regression model with an interaction for being a CAR T provider and the year tested if the annual trend in CCR was different for CAR T providers.

RESULTS: Twenty-four hospitals were identified as CAR T providers, compared to about 3,100 non-CAR T providers. Across the timeframe, the mean CCR for CAR T providers was significantly lower compared to non-CAR T providers (0.26 vs 0.32, p<0.05). There were no significant differences in CCR differences between CAR T providers and non-CAR T providers for individual years, and no significant difference in CCR was observed over time within provider categories. The interaction between provider category and time was non-significant.

CONCLUSIONS: This real-world data revealed that Medicare inpatient CCR patterns for hospitals that have provided CAR T therapies are lower, on average, compared to other hospitals; however, charge practices are not significantly different, charges have not increased for either hospital category during the timeframe, and charge trends have not been different between provider categories.

Code

HPR89

Topic

Economic Evaluation, Health Policy & Regulatory, Study Approaches

Topic Subcategory

Reimbursement & Access Policy

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Oncology